| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | El-Nasir Lalani | Q63643363 |
| P2093 | author name string | Gordon Stamp | |
| Jan Domin | |||
| Paul Abel | |||
| Soha Salama El Sheikh | |||
| P2860 | cites work | Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor | Q22009068 |
| Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells | Q24317507 | ||
| Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation | Q24631073 | ||
| Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor | Q24631156 | ||
| Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells | Q24657518 | ||
| From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells | Q24682910 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Molecular Cloning of Human and Rat Complementary DNA Encoding Androgen Receptors | Q28115447 | ||
| The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells | Q28138197 | ||
| Signaling by distinct classes of phosphoinositide 3-kinases | Q28139034 | ||
| Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance | Q28141690 | ||
| Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity | Q28205398 | ||
| Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells | Q28217019 | ||
| The MAPK signaling cascade | Q28292599 | ||
| Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase | Q28511501 | ||
| Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist | Q28609380 | ||
| Making the connection: coupling of stress-activated ERK/MAPK (extracellular-signal-regulated kinase/mitogen-activated protein kinase) core signalling modules to extracellular stimuli and biological responses | Q28678963 | ||
| HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer | Q61510069 | ||
| Hsp90 Regulates Androgen Receptor Hormone Binding Affinityin Vivo | Q62059794 | ||
| Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN | Q64381461 | ||
| Urogastrone-epidermal growth factor concentrations in prostatic fluid of normal individuals and patients with benign prostatic hypertrophy | Q68960366 | ||
| c-Jun can mediate androgen receptor-induced transactivation | Q71515059 | ||
| Identification of three proline-directed phosphorylation sites in the human androgen receptor | Q71758582 | ||
| Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor | Q71862775 | ||
| MAP kinase module: role in the control of cell proliferation | Q71992334 | ||
| Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer | Q72989706 | ||
| c-Jun targets amino terminus of androgen receptor in regulating androgen-responsive transcription | Q73121984 | ||
| Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade | Q73168346 | ||
| Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells | Q73202210 | ||
| Rapid signalling by androgen receptor in prostate cancer cells | Q73270723 | ||
| c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer | Q73275721 | ||
| Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization | Q73422206 | ||
| Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells | Q73693654 | ||
| ErbB kinases and NDF signaling in human prostate cancer cells | Q73945597 | ||
| HER2 protein expression and gene amplification in androgen-independent prostate cancer | Q74317132 | ||
| Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcinomatous prostate | Q74456040 | ||
| Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor | Q77464583 | ||
| Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma | Q77983272 | ||
| Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer | Q77995576 | ||
| Analysis of protooncogene c-erbB-2 in benign and malignant human prostate | Q78007114 | ||
| Androgen stimulates mitogen-activated protein kinase in human breast cancer cells | Q78083149 | ||
| Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells | Q78206909 | ||
| Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: a review | Q93911679 | ||
| Cellular survival: a play in three Akts | Q29547806 | ||
| New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway | Q29616144 | ||
| Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/protein kinase B. | Q30303890 | ||
| Androgen receptor signalling: comparative analysis of androgen response elements and implication of heat-shock protein 90 and 14-3-3eta | Q32062617 | ||
| Overcoming bcl-2- and p53-mediated resistance in prostate cancer | Q33586871 | ||
| Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy | Q33633919 | ||
| PTEN and prostate cancer | Q33681342 | ||
| Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators. | Q33686869 | ||
| EGF receptor signaling in prostate morphogenesis and tumorigenesis | Q33743859 | ||
| Small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer | Q33853729 | ||
| Cancer statistics, 2000. | Q33895772 | ||
| Phosphoinositide 3-kinase signalling pathways | Q33940898 | ||
| Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer | Q33944430 | ||
| Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1. | Q33960695 | ||
| Androgen receptor signalling in the prostate. | Q34105526 | ||
| The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification | Q34249785 | ||
| In vivo amplification of the androgen receptor gene and progression of human prostate cancer | Q34314274 | ||
| Growth factors and their receptors: new targets for prostate cancer therapy | Q34335662 | ||
| Androgen receptor signaling in androgen-refractory prostate cancer | Q34444942 | ||
| The ups and downs of MEK kinase interactions | Q34453370 | ||
| Androgen-dependent regulation of human MUC1 mucin expression | Q34775040 | ||
| Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer | Q35788601 | ||
| Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. | Q35796528 | ||
| Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells | Q35846108 | ||
| Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation | Q35849279 | ||
| Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression | Q36067596 | ||
| Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor | Q38348552 | ||
| Steroid hormone receptors and their regulation by phosphorylation | Q38351829 | ||
| Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma | Q38474625 | ||
| Alteration of the Tumor Suppressor Gene p53 in a High Fraction of Hormone Refractory Prostate Cancer | Q38480367 | ||
| Elevated serum levels of p105(erbB-2) in patients with advanced-stage prostatic adenocarcinoma | Q39434626 | ||
| Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer | Q39446502 | ||
| Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma | Q39487932 | ||
| Molecular implications of the antiandrogen withdrawal syndrome | Q40403214 | ||
| The mitogen-activated protein kinases, ERK1 and ERK2. | Q40558045 | ||
| Target populations and strategies for chemoprevention trials of prostate cancer | Q40570879 | ||
| Steroid hormone receptor phosphorylation: is there a physiological role? | Q40686365 | ||
| Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation | Q40725486 | ||
| Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells | Q40736171 | ||
| Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state | Q40773957 | ||
| Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. | Q40812297 | ||
| HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. | Q40832627 | ||
| Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression | Q40877541 | ||
| Activation of extracellular signal-regulated kinase in human prostate cancer | Q40928024 | ||
| Androgen receptor phosphorylation | Q40931377 | ||
| Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials | Q40954859 | ||
| Activation of the androgen receptor by polypeptide growth factors and cellular regulators | Q40958221 | ||
| Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines | Q40979803 | ||
| The c-erbB3/HER3 receptor in human cancer. | Q41203891 | ||
| Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP. | Q41337540 | ||
| Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer | Q41344070 | ||
| A potential autocrine loop between heregulin-alpha and erbB-3 receptor in human prostatic adenocarcinoma | Q41366129 | ||
| Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor | Q41435735 | ||
| Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers | Q41463454 | ||
| Molecular and cellular biology of prostate cancer | Q41474856 | ||
| Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor | Q41510695 | ||
| Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. | Q41528424 | ||
| A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. | Q41615181 | ||
| Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones | Q41643600 | ||
| Steroid-independent activation of androgen receptor in androgen-independent prostate cancer: a possible role for the MAP kinase signal transduction pathway? | Q41667115 | ||
| Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process | Q41695916 | ||
| Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides | Q41702970 | ||
| Growth factor involvement in progression of prostate cancer | Q41745741 | ||
| Androgen receptor heterogeneity and phosphorylation in human LNCaP cells | Q41747633 | ||
| Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro | Q42436009 | ||
| Expression of androgen receptor and growth factors in premalignant lesions of the prostate | Q42467183 | ||
| Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates | Q42477282 | ||
| Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas | Q43492345 | ||
| A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy | Q43627769 | ||
| Androgen blocks apoptosis of hormone-dependent prostate cancer cells | Q43675329 | ||
| Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. | Q43708526 | ||
| Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide | Q43821771 | ||
| Phosphoinositide metabolism in human prostate cancer cells in vitro | Q44063536 | ||
| A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens | Q44507804 | ||
| Frequent inactivation of PTEN in prostate cancer cell lines and xenografts | Q47855108 | ||
| Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998. | Q50661098 | ||
| Her-2-neu expression and progression toward androgen independence in human prostate cancer. | Q53800928 | ||
| Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. | Q55032647 | ||
| Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor | Q60594517 | ||
| P433 | issue | 2 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 99-109 | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | Neoplasia | Q2962042 |
| P1476 | title | Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk | |
| P478 | volume | 5 |
| Q45081690 | 5alpha-Androstane-3alpha,17beta-diol activates pathway that resembles the epidermal growth factor responsive pathways in stimulating human prostate cancer LNCaP cell proliferation |
| Q38526448 | A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. |
| Q28389391 | A review of the past, present, and future directions of neoplasia |
| Q28389985 | Coming of Age in the Life of |
| Q64061189 | Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer |
| Q58325235 | EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells |
| Q37627154 | Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth |
| Q89633512 | Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma |
| Q43582537 | Lycopene effects contributing to prostate health |
| Q44920059 | Molecular alterations associated with LNCaP cell progression to androgen independence |
| Q35164684 | Network-based prediction for sources of transcriptional dysregulation using latent pathway identification analysis |
| Q42072658 | Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer--a pilot study. |
| Q33205584 | Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12. |
| Q24650935 | Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling |
| Q39752632 | Trihydrophobin 1 attenuates androgen signal transduction through promoting androgen receptor degradation |
| Q90681456 | pathfindR: An R Package for Comprehensive Identification of Enriched Pathways in Omics Data Through Active Subnetworks |
Search more.